Rory Hunter

Small-cap gold and critical mineral miners could benefit from a multi-year resources cycle, underpinned by rising artificial intelligence investment and energy transition needs, according to Rory Hunter, head of emerging and small companies at SGH, while rising interest rates could weigh on small industrials over the shorter term.

“The opportunity in critical minerals today is one of the most compelling themes we see anywhere in global markets”, he said. “The structural drivers behind it are powerful and we expect that to continue in the years to come.

According to Hunter, Australian small companies stand to benefit, with many critical minerals and gold miners listed on the ASX.

“Resources make up more than 30 per cent of the S&P/ASX Small Ordinaries index, and that’s where we see a significant portion of the opportunity. The long-term tailwinds in gold and critical minerals look very durable,” said Hunter.

“If you look at global trends, the sheer scale of AI-related capital spending and the energy generation and transmission build out required to support it, the demand profile for key commodities like copper, silver, uranium, and a suite of more niche critical minerals becomes increasingly strong.

“Add to that the fact that China is increasingly weaponising supply, you have the ingredients for a sustained period of outperformance in the very resources-heavy small-cap index. These stocks are under-owned relative to their small-cap industrial counterparts, so there’s plenty of room for them to move significantly higher and see a substantial re-rating.”

Reflecting Hunter’s bullishness, prices for silver hit record highs in early December around US$58.84, according to Bloomberg. Copper also rallied to a record of US$11,334 a ton on the London Metal Exchange on 1 December.

Investors have been bullish on copper because of its key role in the clean energy transition, with the critical metal up nearly 30 per cent this year. Uranium prices have also rallied this year.

“The supply-demand dynamics favour ongoing gains in critical minerals companies. AI capital spending, energy generation, energy transmission, and potential productivity improvements will underpin commodities demand. Coupled with the supply-side factors with some supply deficits which drives our bullishness in what could be deemed as a new commodities super-cycle.”

In contrast, the outlook for industrial companies is less bullish, according to Hunter. The potential for a rise in interest rates given Australian inflation is back above the central bank’s 2 per cent to 3 per cent target band could see interest rates rise over the short to medium term, putting pressure on the value of small-cap industrial companies.

“In the near term, there is a consensus view that the path of least resistance for interest rates looks to be potentially higher. That creates potential headwinds for small industrials, which are fully priced but also very well owned.

“Despite those potential headwinds, we do expect that small caps have the potential to continue their outperformance. But it could just come in a change of leadership, moving to resources, away from industrial companies,” said Hunter.

The post SG Hiscock tips critical minerals and gold to power small-cap outperformance in 2026 appeared first on AdviserVoice.

Hamish Tadgell

SG Hiscock & Company has launched a new fund that will invest in Australian medical technology companies.

The SGH Medical Technology Fund will have a social impact focus and aims to provide long-term capital growth by investing in a portfolio of medical technology companies where innovation plays a crucial role in improving global health and economic outcomes.

Rory Hunter, portfolio manager of the Fund, says Australian medical technology is among the best in the world and the Fund will offer investors access to high quality growth companies, both established and start-up.

“Australia’s history of medical breakthroughs includes penicillin, the bionic ear, ultrasounds, spray-on skin, and the cervical cancer vaccine. In addition, there are many research facilities in Australia which are recognised as medical centres of excellence at a global level.

“Investors will also benefit from several tailwinds that are driving innovation and growth in medical research and technology.

“The nature of ageing populations in developed economies has been understood for some time, but we are starting to see the full impact of this demographic trend.  There is ever increasing pressure on healthcare institutions to invest in early intervention and prevention, with research showing that medical care is less effective in improving health outcomes than early intervention strategies.

“The COVID-19 pandemic has added a further layer to this.  We are seeing greater demand for diagnostic testing and healthcare services, and significant government spending to support the industry.  The 2021 Federal Budget included a “patent box” tax break for medical and biotech companies to help encourage research and innovation and we expect further government initiatives to follow this.

“Finally, we believe investors who are interested in social impact investing will find the Fund attractive.  Through its investments in Australian medical technology and innovation, the Fund will actively contribute to the welfare of future generations as well as donating a portion of management fees to Australian medical research and commercialisation.”

The SGH Medical Technology Fund will invest in a mix of established and start-up medical technology companies, listed and unlisted, in Australia and New Zealand.  It will typically hold between 40 and 60 investments.

The Fund will be run by the SGH Emerging Companies Team and will be guided by the SGH Medical Technology Advisory Board, made up of industry leading experts including:

• Brenda Shanahan AO as chair (non-executive director, SG Hiscock & Company; non-executive director, Clinuvel Pharmaceuticals; former chair, St Vincent’s Medical Research Institute; chair, Aitkenhead Centre for Medical Discovery)
• Professor Mark Cook (chair of medicine, St Vincent’s Hospital; chair of medicine, University of Melbourne; state chair, Victoria, Australian and New Zealand Association of Neurologists; director, Graeme Clarke Institute for Biomedical Engineering)
• Sam Lanyon (co-CEO and co-founder, Planet Innovation; executive chair, Lumos Diagnostics).
• Stephen Hiscock (chairman and managing director, SG Hiscock & Company; director, DMP Asset Management)
• Hamish Tadgell (head of research, SG Hiscock & Company; portfolio manager, SGH20)

Additionally, SGH will establish a registered charitable foundation which will be funded by 10% of net revenue from the SGH Medical Technology Fund, including performance fees.

The post SG Hiscock launches medical technology fund appeared first on AdviserVoice.